AusperBio Announces FDA Clearance of IND Application of AHB-137 in Chronic Hepatitis B Treatment

25 Aug 2023
www.prnewswire.com
INDOligonucleotideClinical Study
AHB-137 is cleared for initiation of a clinical trial in CHB patients in the US
AHB-137 is an unconjugated antisense oligonucleotide (ASO) aimed for functional cure of CHB
SAN FRANCISCO, Aug. 25, 2023 /PRNewswire/ --
AusperBio Therapeutics, Inc. and
AusperBio), a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB) infection, today announced
the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application for a clinical trial on AHB-137. The clinical trial in the US is part of a multiregional, randomized, double-blinded, placebo-controlled study, intended to assess the safety, tolerability, pharmacokinetics, and initial efficacy of AHB-137 in CHB patients (clinicaltrials.gov # NCT05717686).
Continue Reading
"The FDA's clearance of our IND application to initiate clinical evaluation of AHB-137 in CHB patients in the United States brings us one step closer to introducing a potential functional cure for people living with HBV." said AusperBio CEO and Co-founder Dr. Guofeng Cheng, "This milestone is a pivotal juncture for AusperBio, underscoring our consistent and outstanding execution in driving innovative therapies towards a functional cure for CHB."
This milestone is a pivotal juncture for AusperBio.
Tweet this
"We are committed to expediting patient access to innovative treatments." Dr. Cheng Yong Yang, CSO and Co-founder of AusperBio highlighted. "Our focus now is on working closely with key opinion leaders to initiate the CHB patient study in the US."
Chronic Hepatitis B (CHB) infection is a liver disease estimated to affect nearly 290 million people worldwide and can cause other chronic complications such as cirrhosis and hepatocellular carcinoma. Although current treatment options can suppress HBV replication, achieving a cure is rare. Therefore, the discovery of a cure for CHB remains an urgent need.
About AusperBio.
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary
Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio's strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.
Media Contact
Email:
[email protected]
Investor Contact
Tel: 650-888-1756 (US)
Email:
[email protected]
SOURCE AusperBio Therapeutics Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.